31 results on '"Mok, T"'
Search Results
2. Supplement to: Variant Creutzfeldt-Jakob disease in a patient with heterozygosity at PRNP codon 129.
3. Overview of current systemic management of EGFR-mutant NSCLC
4. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
5. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
6. Supplement to: First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
7. Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+ NSCLC in a phase 3, randomized, open-label study: KEYNOTE-042: 195TiP
8. NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC: 192TiP
9. LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations: 140PD
10. Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials: 141PD
11. Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6): 138PD
12. Being molecular in the molecular age
13. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
14. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
15. Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer
16. Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials: ID 242
17. Supplement to: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
18. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer
19. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death
20. 4-Methylnitrosamino-1-3-pyridyl-1-butanone (NNK) promotes lung cancer cell survival by stimulating thromboxane A2 and its receptor
21. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
22. Familial occurrence of sequential B-cell lymphoma and myeloproliferative disease
23. A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity
24. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma
25. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy
26. Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors
27. Impact of Sjögrenʼs syndrome on oral health-related quality of life in southern Chinese
28. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)
29. An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy
30. Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial
31. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.